Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
Pediatrix Medical Group (MD) Delivers Q3 2026 Beat and Raises Full-Year EBITDA Guidance

Pediatrix Medical Group (MD) Delivers Q3 2026 Beat and Raises Full-Year EBITDA Guidance

Key Takeaways

  • Pediatrix Medical Group reported third-quarter 2026 net revenue of $501.4 million, up 1.7% year over year and slightly above analyst consensus estimates.
  • Adjusted earnings per share (EPS) came in at $0.72, beating consensus estimates of roughly $0.65 and rising from $0.67 in the prior-year quarter.
  • Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $85.5 million, exceeding expectations even as it declined modestly from $87.3 million a year earlier.
  • Management raised its full-year 2026 adjusted EBITDA guidance to a range of $290 million to $300 million, up from its prior $280 million to $300 million outlook.
  • Same-unit revenue grew 0.6%, supported by a favorable shift in payor mix and higher patient acuity in neonatology.
  • For additional context, explore Pediatrix Medical Group's Major News, Today's Price Move, Price Targets, and Forecast pages.
  • Discover AI-driven trade ideas and market opportunities with Trending AI Robots.

Earnings Context and Why It Matters

As a leading physician-services group focused on prenatal, neonatal, and pediatric care, MD sits at the intersection of healthcare demand, reimbursement trends, and hospital relationships. Its quarterly results offer investors a read on patient volumes, payor mix, and the effectiveness of its revenue cycle management. The third quarter is particularly important because it follows a stretch of consistent earnings beats and comes as management works to improve operating efficiency while evaluating acquisitions in the women's and children's space. With shares having already climbed sharply in 2026, this report tests whether the company's margin and cash-collection momentum can justify the market's elevated expectations.

Reported Results

For the three months ended September 30, 2026, Pediatrix Medical Group reported net revenue of $501.4 million, a 1.7% increase from $492.9 million in the prior-year period. The result modestly exceeded consensus estimates of roughly $497 million. Growth reflected a 1.1% contribution from non-same-unit activity tied to recent acquisitions, partially offset by practice dispositions, plus a 0.6% increase in same-unit revenue.

On a GAAP basis, net income was $47.0 million, or $0.59 per diluted share, compared with $71.7 million, or $0.84 per share, a year earlier — a period that benefited from a $20.9 million gain on investments in divested businesses. Adjusted EPS, which excludes non-recurring items such as amortization, stock-based compensation, and restructuring costs, was $0.72, up from $0.67 in the prior-year quarter and above the consensus estimate of about $0.65.

Adjusted EBITDA was $85.5 million, compared with $87.3 million in the same quarter last year. The modest decline reflected higher expenses relative to revenue growth at existing units, partially offset by favorable contributions from recent acquisitions. Same-unit revenue from net reimbursement-related factors rose 0.3%, helped by a favorable payor mix, higher administrative fees from hospital partners, and increased patient acuity in neonatology. The percentage of services reimbursed by commercial and other non-government payors improved by 70 basis points. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Reaction and Investor Sentiment

Heading into the report, investor sentiment around Pediatrix Medical Group had been notably positive, with the stock up about 35% year to date versus a roughly 13% gain for the S&P 500. Analysts had maintained a generally neutral "Hold" stance, and the third-quarter beat on both revenue and adjusted EPS, combined with the upward revision to full-year adjusted EBITDA guidance, reinforced the narrative of improving operational execution. The key drivers of investor interpretation include sustained strength in cash collections, a favorable payor mix, and continued share repurchases, which reduced the weighted average share count and supported per-share results. The main offsetting factor is the modest year-over-year decline in adjusted EBITDA, which highlights lingering cost pressures.

Forward Outlook and Key Factors to Monitor

Looking ahead, the most important signal is management's decision to raise full-year 2026 adjusted EBITDA guidance to a range of $290 million to $300 million, with the midpoint of $295 million sitting above consensus estimates near $289 million. This suggests the company expects its margin and reimbursement trends to remain supportive through the fourth quarter.

Investors should watch same-unit patient volume trends, particularly neonatal intensive care unit (NICU) days and hospital-based services, which have been a persistent source of softness. Reimbursement-related factors, including payor mix and administrative fees from hospital contracts, will also remain central, since these have driven much of the recent revenue growth even as volumes lag.

Cost management is another key area. Practice salaries and benefits remain the largest expense line, and any acceleration in clinical wage inflation could pressure margins. The company's continued focus on revenue cycle management (RCM) efficiency and its willingness to pursue acquisitions in adjacent women's and children's specialties will shape the growth trajectory. Finally, the balance sheet remains a source of optionality, with no borrowings under its revolving credit facility and an active share-repurchase program supporting per-share results. From what I see, these elements together point to a measured but constructive setup for the quarters ahead.

Using Tickeron’s AI Tools in Practice

In my own workflow, Tickeron’s AI Screener helps me quickly filter for stocks showing similar earnings momentum and technical setups within the healthcare sector. It lets me scan thousands of names using customizable criteria like industry, market cap, and AI-driven signals, which saves time when cross-checking results like these against peers. I find it especially useful for spotting patterns around earnings beats and guidance changes without manual digging through dozens of screens.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MD

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


MD's RSI Oscillator leaves overbought zone

The 10-day RSI Oscillator for MD moved out of overbought territory on November 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 21 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MD as a result. In 71 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.

The Moving Average Convergence Divergence Histogram (MACD) for MD turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 34 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for MD crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 61%.

Following a +1.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where MD advanced for three days, in 195 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

MD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 132 of 196 cases where MD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. MD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.886) is normal, around the industry mean (204.532). P/E Ratio (14.690) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.120) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.153) among similar stocks. P/S Ratio (1.119) is also within normal values, averaging (2.688).

The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.37B. The market cap for tickers in the group ranges from 20.9K to 107.17B. HCA holds the highest valuation in this group at 107.17B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -12%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was 0%. CHE experienced the highest price growth at 0%, while NIVF experienced the biggest fall at -88%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 13%. For the same stocks of the Industry, the average monthly volume growth was 102% and the average quarterly volume growth was 58%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 49
Price Growth Rating: 59
SMR Rating: 66
Profit Risk Rating: 83
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of medical services

Industry HospitalNursingManagement

Industry
Medical Or Nursing Services
Address
1301 Concord Terrace
Phone
+1 954 384-0175
Employees
6575
Web
https://www.pediatrix.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.